Case Report
After Failure With Acenocoumarol, Rivaroxaban in Antiphospholipid Syndrome: A Report of 2 Cases
Rivaroxabán en síndrome antifosfolipídico tras fracaso con acenocumarol: a propósito de 2 casos
Javier José Mateos Rodrígueza,
, David Bellidob, David Castroa, José Portillo Sánchezb, Raúl Vanegasc, Alicia Núñez Garcíad
Corresponding author
a Servicio de Reumatología, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain
b Servicio de Medicina Interna, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain
c Servicio de Hematología, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain
d Medicina de Familia, Ciudad Real, Spain
Read
6186
Timeswas read the article
1913
Total PDF
4273
Total HTML
Share statistics
array:24 [ "pii" => "S217357431830114X" "issn" => "21735743" "doi" => "10.1016/j.reumae.2017.04.007" "estado" => "S300" "fechaPublicacion" => "2019-09-01" "aid" => "1056" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología" "copyrightAnyo" => "2017" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Reumatol Clin. 2019;15:e33-e35" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1 "HTML" => 1 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S1699258X17301018" "issn" => "1699258X" "doi" => "10.1016/j.reuma.2017.04.010" "estado" => "S300" "fechaPublicacion" => "2019-09-01" "aid" => "1056" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Reumatol Clin. 2019;15:e33-e35" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1282 "formatos" => array:3 [ "EPUB" => 88 "HTML" => 692 "PDF" => 502 ] ] "es" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Caso clínico</span>" "titulo" => "Rivaroxabán en síndrome antifosfolipídico tras fracaso con acenocumarol: a propósito de 2 casos" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "e33" "paginaFinal" => "e35" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "After failure with acenocoumarol, rivaroxaban in antiphospholipid syndrome: A report of 2 cases" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1060 "Ancho" => 1570 "Tamanyo" => 194677 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">A) Cardiorresonancia con imagen eco de gradiente de 4 cámaras. Lesión polipoidea endocavitaria de 12<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>9<span class="elsevierStyleHsp" style=""></span>mm dependiente del endocardio en la región apical del ventrículo izquierdo, isointensa sin realce significativo tras contraste. B) Angiotomografía computarizada de troncos supraaórticos con imagen de corte axial. En el sistema carotídeo derecho se aprecia trombo adherido a la pared de la arteria carótida interna derecha desde su origen, que reduce su calibre y que acaba ocluyendo la arteria. C) Tomografía computarizada abdominal que muestra trombosis de la vena esplénica, de la porta hepatis con extensa área de infarto esplénico.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Javier José Mateos Rodríguez, David Bellido, David Castro, José Portillo Sánchez, Raúl Vanegas, Alicia Núñez García" "autores" => array:6 [ 0 => array:2 [ "nombre" => "Javier José" "apellidos" => "Mateos Rodríguez" ] 1 => array:2 [ "nombre" => "David" "apellidos" => "Bellido" ] 2 => array:2 [ "nombre" => "David" "apellidos" => "Castro" ] 3 => array:2 [ "nombre" => "José" "apellidos" => "Portillo Sánchez" ] 4 => array:2 [ "nombre" => "Raúl" "apellidos" => "Vanegas" ] 5 => array:2 [ "nombre" => "Alicia" "apellidos" => "Núñez García" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S217357431830114X" "doi" => "10.1016/j.reumae.2017.04.007" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S217357431830114X?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X17301018?idApp=UINPBA00004M" "url" => "/1699258X/0000001500000005/v1_201910230648/S1699258X17301018/v1_201910230648/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2173574318301333" "issn" => "21735743" "doi" => "10.1016/j.reumae.2018.10.002" "estado" => "S300" "fechaPublicacion" => "2019-09-01" "aid" => "1055" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Reumatol Clin. 2019;15:e36-e38" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Case Report</span>" "titulo" => "Neurological Manifestations of Behçet's Disease: Case Report and Literature Review" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "e36" "paginaFinal" => "e38" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Manifestaciones neurológicas de la enfermedad de Behçet: descripción de un caso y revisión de la literatura" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 640 "Ancho" => 850 "Tamanyo" => 51104 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Venous transverse 2-dimensional time-of-flight magnetic resonance angiography; venous thrombosis in the left transverse sinus with slight prolongation into left sigmoid sinus.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Alba López Bravo, Carlos Parra Soto, Elena Bellosta Diago, Álvaro Cecilio Irazola, Sonia Santos-Lasaosa" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Alba" "apellidos" => "López Bravo" ] 1 => array:2 [ "nombre" => "Carlos" "apellidos" => "Parra Soto" ] 2 => array:2 [ "nombre" => "Elena" "apellidos" => "Bellosta Diago" ] 3 => array:2 [ "nombre" => "Álvaro" "apellidos" => "Cecilio Irazola" ] 4 => array:2 [ "nombre" => "Sonia" "apellidos" => "Santos-Lasaosa" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S1699258X17301006" "doi" => "10.1016/j.reuma.2017.04.009" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X17301006?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574318301333?idApp=UINPBA00004M" "url" => "/21735743/0000001500000005/v1_201910260908/S2173574318301333/v1_201910260908/en/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S2173574319301315" "issn" => "21735743" "doi" => "10.1016/j.reumae.2017.05.011" "estado" => "S300" "fechaPublicacion" => "2019-09-01" "aid" => "1061" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Reumatol Clin. 2019;15:e30-e32" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Case report</span>" "titulo" => "Late-onset Cogan's syndrome associated with large-vessel vasculitis" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "e30" "paginaFinal" => "e32" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Síndrome de Cogan de inicio tardío asociado con una vasculitis de gran vaso" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 939 "Ancho" => 950 "Tamanyo" => 63097 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Axial <span class="elsevierStyleSup">18</span>FDG PET/CT view showing an increased uptake of <span class="elsevierStyleSup">18</span>F-fluorodeoxyglucose at the thoracic aorta (arrow).</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Iván Cabezas-Rodríguez, Anahy Brandy-García, Carlos Rodríguez-Balsera, Paloma Rozas-Reyes, Belen Fernández-Llana, Luis Arboleya-Rodríguez" "autores" => array:6 [ 0 => array:2 [ "nombre" => "Iván" "apellidos" => "Cabezas-Rodríguez" ] 1 => array:2 [ "nombre" => "Anahy" "apellidos" => "Brandy-García" ] 2 => array:2 [ "nombre" => "Carlos" "apellidos" => "Rodríguez-Balsera" ] 3 => array:2 [ "nombre" => "Paloma" "apellidos" => "Rozas-Reyes" ] 4 => array:2 [ "nombre" => "Belen" "apellidos" => "Fernández-Llana" ] 5 => array:2 [ "nombre" => "Luis" "apellidos" => "Arboleya-Rodríguez" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574319301315?idApp=UINPBA00004M" "url" => "/21735743/0000001500000005/v1_201910260908/S2173574319301315/v1_201910260908/en/main.assets" ] "en" => array:20 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Case Report</span>" "titulo" => "After Failure With Acenocoumarol, Rivaroxaban in Antiphospholipid Syndrome: A Report of 2 Cases" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "e33" "paginaFinal" => "e35" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Javier José Mateos Rodríguez, David Bellido, David Castro, José Portillo Sánchez, Raúl Vanegas, Alicia Núñez García" "autores" => array:6 [ 0 => array:4 [ "nombre" => "Javier José" "apellidos" => "Mateos Rodríguez" "email" => array:1 [ 0 => "jjmateosr@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "David" "apellidos" => "Bellido" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "David" "apellidos" => "Castro" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 3 => array:3 [ "nombre" => "José" "apellidos" => "Portillo Sánchez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 4 => array:3 [ "nombre" => "Raúl" "apellidos" => "Vanegas" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 5 => array:3 [ "nombre" => "Alicia" "apellidos" => "Núñez García" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] ] ] ] "afiliaciones" => array:4 [ 0 => array:3 [ "entidad" => "Servicio de Reumatología, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Medicina Interna, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Servicio de Hematología, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Medicina de Familia, Ciudad Real, Spain" "etiqueta" => "d" "identificador" => "aff0020" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Rivaroxabán en síndrome antifosfolipídico tras fracaso con acenocumarol: a propósito de 2 casos" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 855 "Ancho" => 1267 "Tamanyo" => 144531 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">(A) Cardiac magnetic resonance with gradient-echo images of 4 chambers. Intracavitary polypoid lesion 12<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>9<span class="elsevierStyleHsp" style=""></span>mm dependent on the endocardium in the apical region of the left ventricle, isointense with no significant contrast enhancement. (B) CT angiography of supra-aortic trunks with axial slice image. A thrombus can be observed in the right carotid system adhering to the right internal carotid artery from its origin, reducing its calibre and resulting in occlusion of the artery. (C) Abdominal CT showing thrombosis of the splenic vein of the porta hepatis with an extensive are of splenic infarction.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Antiphospholipid syndrome (APS) is an autoimmune disease characterised by thrombosis or foetal loss associated with the presence of specific persistent antibodies (lupus anticoagulant, anticardiolipin and/or anti-beta2-glycoprotein). The standard treatment for patients with a history of venous thromboembolic disease (VTED) in the acute phase is unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) followed by a vitamin K antagonist (VKA). If VKA fails, the therapeutic range can be increased, prescribing an LMWH and/or combining acetylsalicylic acid (especially if there is associated arterial thrombosis).<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">1</span></a> We present 2 clinical cases of VTED in the context of APS where rivaroxaban was used after failing to achieve adequate control with VKA.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Clinical Observation</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Clinical Case 1</span><p id="par0010" class="elsevierStylePara elsevierViewall">A 30-year-old male patient, with a diagnosis of primary APS due to lupus anticoagulant, <span class="elsevierStyleItalic">with no other history of interest</span>, who started manifestations of recurring and chronic VTED in the lower limbs at the age of 17. Treatment with acenocoumarol was started, and the patient had a labile international normalised ratio (INR), despite exhaustive controls. The patient required supplementary LMWH when he did not achieve the therapeutic range. At the age of 25, after study of a transient ischaemic attack, an intracardiac thrombus that was refractory to intravenous sodium heparin was found, for which the patient was operated (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>A). Treatment was intensified with acenocoumarol with an INR of between 2.5 and 3.5, combined with 100<span class="elsevierStyleHsp" style=""></span>mg aspirin every 24<span class="elsevierStyleHsp" style=""></span>h. A year later, the patient had a stroke of the middle right cerebral artery secondary to thrombosis of the right internal carotid artery (days earlier his INR was near 7, and therefore his regimen was changed; he had an INR of 1.3 on arrival at the hospital). He underwent intravenous fibrinolysis which was not successful (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>B). The time in therapeutic range (TTR), according to the Rosendaal method, of the acenocoumarol over the year before the ischaemic attack was 46%. Subsequently, having failed to achieve optimal control with acenocoumarol, the patient was changed to warfarin and continued to have highly fluctuating INR levels, therefore treatment was started with rivaroxaban 20<span class="elsevierStyleHsp" style=""></span>mg every 24<span class="elsevierStyleHsp" style=""></span>h as compassionate use. After 3 years of follow-up of the rivaroxaban treatment, the patient had had no further thrombotic events, and had maintained enzyme-linked immunosorbent assay <span class="elsevierStyleSmallCaps">d</span>-Dimer levels within the normal range.</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Clinical Case 2</span><p id="par0015" class="elsevierStylePara elsevierViewall">A 26-year-old male, with APS due to lupus anticoagulant associated with systemic lupus erythematous (SLE) that had started 10 years earlier with joint, skin and kidney involvement (diffuse proliferative glomerulonephritis with nephrotic syndrome). Under maintenance treatment with mycophenolate mofetil 1000<span class="elsevierStyleHsp" style=""></span>mg/12<span class="elsevierStyleHsp" style=""></span>h, prednisone 2.5<span class="elsevierStyleHsp" style=""></span>mg, aspirin 100<span class="elsevierStyleHsp" style=""></span>mg, losartan 50<span class="elsevierStyleHsp" style=""></span>mg and hydroxychloroquine 200<span class="elsevierStyleHsp" style=""></span>mg every 24<span class="elsevierStyleHsp" style=""></span>h, with stability of the SLE and no signs of kidney involvement. The patient had an episode of pulmonary thromboembolism at the age of 19 and started treatment with acenocoumarol. Three years later, he had an episode of VTED in the lower left limb, which was not in the therapeutic range (INR 1.2). Subsequently he maintained more exhaustive controls of VKA and supplementary LMWH, if it was necessary. At the age of 24, he suffered a splenic infarction secondary to thrombosis of the splenoportal axis (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a><span class="elsevierStyleSmallCaps">C</span>), with an INR of 3.4 and TTR of 71% over the year before the event. In the acute phase he received treatment with LMWH at therapeutic doses (enoxaparin mg/kg/12<span class="elsevierStyleHsp" style=""></span>h), and after clinical and radiological stability was achieved continued with rivaroxaban 20<span class="elsevierStyleHsp" style=""></span>mg/24<span class="elsevierStyleHsp" style=""></span>h as compassionate use. Since then no further VTED event over a follow-up period of 2 years has been observed on X-rays, checkups and lab tests.</p></span></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Discussion</span><p id="par0020" class="elsevierStylePara elsevierViewall">We present 2 clinical cases of thromboembolic disease for which treatment with rivaroxaban managed to stabilise APS after failure with antivitamin K. Traditionally UFH or LMWH have been used in the acute phase, sequenced to AVK. For refractory cases, in maintenance therapy with, AVK the INR range of the AVK agents has been increased or LMWH used, combined with anticoagulants depending on the case.<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">1</span></a> Prolonged used of low molecular weight heparin is harmful to the patient because it is administered subcutaneously, it causes discomfort, especially locally at the puncture site, and there is the possibility of adverse effects, such as reduced bone mineral density, thrombocytopenia and hypertransaminasaemia.</p><p id="par0025" class="elsevierStylePara elsevierViewall">The therapeutic target of the new oral anticoagulants (NOAC), such as rivaroxaban (anti-Xa), have a similar mechanism of action to that of LMWH. Because this is a drug with a predictable action and low drug interaction rate, it has a promising future for patients who have been poorly controlled with the classical anticoagulant therapy. Furthermore, rivaroxaban, according to recent research, might have the additional benefit of limiting complement activation,<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">2</span></a> and in results of the RAPS study (phase II) is not inferior to warfarin for APS.<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">3</span></a> NOACs have been used for APS, usually with favourable results.<a class="elsevierStyleCrossRefs" href="#bib0070"><span class="elsevierStyleSup">4–7</span></a> The series published by Malec et al. is worthy of note, with 56 patients (49 treated with rivaroxaban) with a mean follow-up of 22 months, and 5.8% recurrence of VTED per year.<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">5</span></a> In the research studies by Haladyj and Olesinska on 23 patients and Son et al. on 12 patients treated with rivaroxaban, 1 and 2 cases recurred, respectively.<a class="elsevierStyleCrossRefs" href="#bib0070"><span class="elsevierStyleSup">4,7</span></a> Development of thrombotic events should also be mentioned after replacing warfarin with a NOAC, as in the study published by Schaefer et al. with a series of 3 patients (one with dabigatran and 2 with rivaroxaban<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">8</span></a>), and one case of catastrophic APS after changing warfarin for rivaroxaban.<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">9</span></a> Clinical trials are currently being developed to determine the role of the NACOs in APS.<a class="elsevierStyleCrossRefs" href="#bib0065"><span class="elsevierStyleSup">3,10</span></a></p><p id="par0030" class="elsevierStylePara elsevierViewall">In both clinical cases (one due to poor control of anticoagulation with fluctuating INR levels, and the other with thrombosis phenomena despite appropriate oral anticoagulation with AVK), treatment with rivaroxaban was proposed with check-up, lab test and imaging follow-up, without revealing any new thrombotic phenomena, and showing good control of APS.</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Conclusions</span><p id="par0035" class="elsevierStylePara elsevierViewall">Treatment with rivaroxaban could be considered a therapeutic alternative for patients with APS not controlled with AVK. New research studies will establish the role of the NACOs in APS.</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Ethical Responsibilities</span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Protection of people and animals</span><p id="par0040" class="elsevierStylePara elsevierViewall">The authors declare that neither human nor animal testing has been carried out under this research.</p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Data confidentiality</span><p id="par0045" class="elsevierStylePara elsevierViewall">The authors declare that they have complied with their work centre protocols for the publication of patient data.</p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Right to privacy and informed consent</span><p id="par0050" class="elsevierStylePara elsevierViewall">The authors have obtained the informed consent of the patients and/or subjects referred to in the article. This document is held by the corresponding author.</p></span></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Conflict of Interests</span><p id="par0055" class="elsevierStylePara elsevierViewall">The authors have no conflict of interest to declare.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:11 [ 0 => array:3 [ "identificador" => "xres1258195" "titulo" => "Abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0005" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1165530" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres1258196" "titulo" => "Resumen" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0010" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec1165529" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:3 [ "identificador" => "sec0010" "titulo" => "Clinical Observation" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "Clinical Case 1" ] 1 => array:2 [ "identificador" => "sec0020" "titulo" => "Clinical Case 2" ] ] ] 6 => array:2 [ "identificador" => "sec0025" "titulo" => "Discussion" ] 7 => array:2 [ "identificador" => "sec0030" "titulo" => "Conclusions" ] 8 => array:3 [ "identificador" => "sec0035" "titulo" => "Ethical Responsibilities" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0040" "titulo" => "Protection of people and animals" ] 1 => array:2 [ "identificador" => "sec0045" "titulo" => "Data confidentiality" ] 2 => array:2 [ "identificador" => "sec0050" "titulo" => "Right to privacy and informed consent" ] ] ] 9 => array:2 [ "identificador" => "sec0055" "titulo" => "Conflict of Interests" ] 10 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2017-02-28" "fechaAceptado" => "2017-04-12" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1165530" "palabras" => array:4 [ 0 => "Antiphospholipid syndrome" 1 => "Rivaroxaban" 2 => "Thromboembolic disease" 3 => "Acenocoumarol" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec1165529" "palabras" => array:4 [ 0 => "Sindrome antifosfolípido" 1 => "Rivaroxabán" 2 => "Enfermedad tromboembólica" 3 => "Acenocumarol" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Antiphospholipid syndrome is characterised by abortions or thrombotic phenomena associated with specific antibodies. Anticoagulant therapy is based on vitamin K antagonists. We present two cases in which the use of rivaroxaban achieved control of the disease after the failure of acenocoumarol.</p></span>" ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">El síndrome antifosfolipídico se caracteriza por abortos o fenómenos trombóticos asociado a anticuerpos específicos. El tratamiento se basa en la anticoagulación con los antagonistas de la vitamina K. Presentamos 2 casos en los que el empleo del rivaroxabán ha logrado controlar la enfermedad tras su fracaso con acenocumarol.</p></span>" ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Mateos Rodríguez JJ, Bellido D, Castro D, Portillo Sánchez J, Vanegas R, Núñez García A. Rivaroxabán en síndrome antifosfolipídico tras fracaso con acenocumarol: a propósito de 2 casos. Reumatol Clin. 2019;15:e33–e35.</p>" ] ] "multimedia" => array:1 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 855 "Ancho" => 1267 "Tamanyo" => 144531 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">(A) Cardiac magnetic resonance with gradient-echo images of 4 chambers. Intracavitary polypoid lesion 12<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>9<span class="elsevierStyleHsp" style=""></span>mm dependent on the endocardium in the apical region of the left ventricle, isointense with no significant contrast enhancement. (B) CT angiography of supra-aortic trunks with axial slice image. A thrombus can be observed in the right carotid system adhering to the right internal carotid artery from its origin, reducing its calibre and resulting in occlusion of the artery. (C) Abdominal CT showing thrombosis of the splenic vein of the porta hepatis with an extensive are of splenic infarction.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:10 [ 0 => array:3 [ "identificador" => "bib0055" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D. Erkan" 1 => "C.L. Aguiar" 2 => "D. Andrade" 3 => "H. Cohen" 4 => "M.J. Cuadrado" 5 => "A. Danowski" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.autrev.2014.01.053" "Revista" => array:6 [ "tituloSerie" => "Autoimmun Rev" "fecha" => "2014" "volumen" => "13" "paginaInicial" => "685" "paginaFinal" => "696" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24468415" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0060" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D.R. Arachchillage" 1 => "I.J. Mackie" 2 => "M. Efthymiou" 3 => "A. Chitolie" 4 => "B.J. Hunt" 5 => "D.A. Isenberg" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/jth.13475" "Revista" => array:6 [ "tituloSerie" => "J Thromb Haemost" "fecha" => "2016" "volumen" => "14" "paginaInicial" => "2177" "paginaFinal" => "2186" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27541499" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0065" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "H. Cohen" 1 => "B.J. Hunt" 2 => "M. Efthymiou" 3 => "D.R. Arachchillage" 4 => "I.J. Mackie" 5 => "S. Clawson" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S2352-3026(16)30079-5" "Revista" => array:6 [ "tituloSerie" => "Lancet Haematol" "fecha" => "2016" "volumen" => "3" "paginaInicial" => "e426" "paginaFinal" => "e436" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27570089" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0070" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Rivaroxaban a safe therapeutic option in patients with antiphospholipid syndrome? Our experience in 23 cases" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "E. Haladyj" 1 => "M. Olesinska" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.5114/reum.2016.61217" "Revista" => array:6 [ "tituloSerie" => "Reumatologia" "fecha" => "2016" "volumen" => "54" "paginaInicial" => "146" "paginaFinal" => "149" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27504026" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0075" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "K. Malec" 1 => "T. Goralczyk" 2 => "A. Undas" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Thromb Res" "fecha" => "2017" "volumen" => "152" "paginaInicial" => "93" "paginaFinal" => "97" ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0080" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "F. Signorelli" 1 => "F. Nogueira" 2 => "V. Domingues" 3 => "H.A. Mariz" 4 => "R.A. Levy" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s10067-015-3030-y" "Revista" => array:6 [ "tituloSerie" => "Clin Rheumatol" "fecha" => "2016" "volumen" => "35" "paginaInicial" => "801" "paginaFinal" => "805" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26219490" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0085" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The use of rivaroxaban in patients with antiphospholipid syndrome: a series of 12 cases" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "M. Son" 1 => "E. Wypasek" 2 => "M. Celinska-Lowenhoff" 3 => "A. Undas" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.thromres.2015.01.028" "Revista" => array:6 [ "tituloSerie" => "Thromb Res" "fecha" => "2015" "volumen" => "135" "paginaInicial" => "1035" "paginaFinal" => "1036" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25669601" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0090" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "J.K. Schaefer" 1 => "R.D. McBane" 2 => "D.F. Black" 3 => "L.N. Williams" 4 => "K.G. Moder" 5 => "W.E. Wysokinski" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1160/TH14-03-0272" "Revista" => array:6 [ "tituloSerie" => "Thromb Haemost" "fecha" => "2014" "volumen" => "112" "paginaInicial" => "947" "paginaFinal" => "950" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25118790" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0095" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Catastrophic antiphospholipid syndrome on switching from warfarin to rivaroxaban" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "M.P. Crowley" 1 => "M.J. Cuadrado" 2 => "B.J. Hunt" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.thromres.2017.03.006" "Revista" => array:6 [ "tituloSerie" => "Thromb Res" "fecha" => "2017" "volumen" => "153" "paginaInicial" => "37" "paginaFinal" => "39" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28319823" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0100" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "V. Pengo" 1 => "A. Banzato" 2 => "E. Bison" 3 => "G. Zoppellaro" 4 => "J.S. Padayattil" 5 => "G. Denas" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1177/0961203315611495" "Revista" => array:6 [ "tituloSerie" => "Lupus" "fecha" => "2016" "volumen" => "25" "paginaInicial" => "301" "paginaFinal" => "306" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26466613" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/21735743/0000001500000005/v1_201910260908/S217357431830114X/v1_201910260908/en/main.assets" "Apartado" => array:4 [ "identificador" => "43296" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Case report" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/21735743/0000001500000005/v1_201910260908/S217357431830114X/v1_201910260908/en/main.pdf?idApp=UINPBA00004M&text.app=https://reumatologiaclinica.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S217357431830114X?idApp=UINPBA00004M" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 2 | 4 | 6 |
| 2024 October | 58 | 35 | 93 |
| 2024 September | 77 | 20 | 97 |
| 2024 August | 92 | 53 | 145 |
| 2024 July | 74 | 21 | 95 |
| 2024 June | 97 | 40 | 137 |
| 2024 May | 76 | 46 | 122 |
| 2024 April | 95 | 42 | 137 |
| 2024 March | 87 | 37 | 124 |
| 2024 February | 61 | 31 | 92 |
| 2024 January | 57 | 20 | 77 |
| 2023 December | 45 | 32 | 77 |
| 2023 November | 70 | 52 | 122 |
| 2023 October | 55 | 25 | 80 |
| 2023 September | 118 | 50 | 168 |
| 2023 August | 117 | 27 | 144 |
| 2023 July | 103 | 26 | 129 |
| 2023 June | 71 | 28 | 99 |
| 2023 May | 82 | 24 | 106 |
| 2023 April | 94 | 9 | 103 |
| 2023 March | 81 | 35 | 116 |
| 2023 February | 93 | 29 | 122 |
| 2023 January | 65 | 11 | 76 |
| 2022 December | 110 | 37 | 147 |
| 2022 November | 100 | 32 | 132 |
| 2022 October | 99 | 43 | 142 |
| 2022 September | 109 | 35 | 144 |
| 2022 August | 76 | 40 | 116 |
| 2022 July | 82 | 43 | 125 |
| 2022 June | 61 | 43 | 104 |
| 2022 May | 70 | 33 | 103 |
| 2022 April | 83 | 52 | 135 |
| 2022 March | 76 | 55 | 131 |
| 2022 February | 80 | 46 | 126 |
| 2022 January | 93 | 61 | 154 |
| 2021 December | 86 | 45 | 131 |
| 2021 November | 60 | 41 | 101 |
| 2021 October | 129 | 56 | 185 |
| 2021 September | 40 | 36 | 76 |
| 2021 August | 51 | 50 | 101 |
| 2021 July | 35 | 28 | 63 |
| 2021 June | 69 | 39 | 108 |
| 2021 May | 96 | 45 | 141 |
| 2021 April | 157 | 66 | 223 |
| 2021 March | 80 | 43 | 123 |
| 2021 February | 73 | 28 | 101 |
| 2021 January | 52 | 25 | 77 |
| 2020 December | 69 | 21 | 90 |
| 2020 November | 59 | 26 | 85 |
| 2020 October | 45 | 18 | 63 |
| 2020 September | 79 | 32 | 111 |
| 2020 August | 41 | 25 | 66 |
| 2020 July | 31 | 17 | 48 |
| 2020 June | 61 | 25 | 86 |
| 2020 May | 47 | 12 | 59 |
| 2020 April | 69 | 17 | 86 |
| 2020 March | 34 | 1 | 35 |
| 2019 November | 1 | 0 | 1 |
Show all
